ABVC BIOPHARMA INC (ABVC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.96-3.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ABVC
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | FY 2013 | FY 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 0.3 | 0.5 | 0.2 | 1.0 | 0.4 | 0.5 | 0.7 | — | — | — | 0.0 | — | 0.0 | 0.0 | 0.0 |
| Total Revenues | — | — | 0.5 | 0.2 | 1.0 | 0.4 | 0.5 | 0.7 | — | — | — | 0.0 | — | 0.0 | 0.0 | 0.0 |
| Cost of Revenues | — | — | 0.0 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | — | 0.0 | 0.0 | 0.0 | — | — | — | — |
| Gross Profit | — | — | 0.5 | (0.1) | 0.7 | 0.4 | 0.5 | 0.7 | — | (0.0) | (0.0) | 0.0 | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 2.8 | 2.9 | 2.3 | 5.4 | 6.1 | 5.7 | 4.3 | 3.1 | 1.6 | 0.7 | 0.6 | — | — | — | — | — |
| R&D Expenses | 0.1 | 0.1 | 0.2 | 1.1 | 2.7 | 1.0 | 0.5 | 1.0 | 1.0 | 3.2 | 10.0 | — | — | — | — | — |
| Other Operating Expenses, Total | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.7 |
| Operating Income | (5.7) | (7.2) | (4.7) | (6.8) | (15.1) | (11.7) | (8.5) | (3.5) | (2.8) | (4.0) | (11.0) | — | — | (0.2) | (1.1) | (1.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.4 | 0.8 | 1.3 | 0.3 | 0.2 | 0.4 | 0.5 | 0.5 | 0.1 | 0.0 | 0.0 | — | 0.0 | 0.1 | 0.2 |
| Interest & Investment Income | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — |
| Net Interest Expenses | — | — | — | 1.1 | 0.1 | 0.2 | 0.3 | 0.5 | 0.5 | 0.1 | 0.0 | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (1.1) | (1.2) | (0.7) | (1.3) | (0.4) | 0.5 | (2.3) | (0.6) | (3.6) | (0.1) | (0.0) | — | — | (0.0) | 0.1 | — |
| Asset Writedown | — | — | — | — | 0.1 | 0.7 | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (6.8) | (8.4) | (5.4) | (8.0) | (15.5) | (11.2) | (10.8) | (4.0) | (6.4) | (4.1) | (11.0) | — | — | — | — | — |
| Income Tax Expense | — | 0.0 | (0.1) | 0.3 | 0.8 | 0.8 | (0.2) | (0.1) | (0.4) | 0.0 | 0.0 | — | — | 0.0 | 0.1 | — |
| Net Income | ||||||||||||||||
| Minority Interest | (0.5) | (0.5) | (0.4) | (0.5) | 0.1 | 0.8 | (10.6) | — | — | — | — | — | — | — | — | — |
| Net Income | (6.3) | (7.9) | (4.9) | (7.8) | (16.4) | (12.8) | (10.6) | (3.9) | (6.1) | (4.1) | (11.0) | (0.0) | (0.0) | (0.2) | (1.1) | (1.2) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.24) | (0.39) | (0.42) | (1.80) | (5.19) | (0.51) | (0.50) | — | (0.02) | (0.02) | (0.06) | — | — | — | — | — |
| Diluted EPS | (0.24) | (0.39) | (0.42) | (1.80) | (5.19) | (0.51) | (0.50) | — | (0.02) | (0.02) | (0.06) | — | — | — | — | — |
| Basic Weighted Avg Shares | 26.1 | 20.1 | 11.7 | 4.3 | 3.2 | 25.1 | 19.7 | — | 213.9 | 212.6 | 194.0 | 5.0 | — | — | — | 9.7 |
| Diluted Weighted Avg Shares | 26.1 | 20.1 | 11.7 | 4.3 | 3.2 | 25.1 | 19.7 | — | 213.9 | 212.6 | 194.0 | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | (15.1) | (11.7) | — | — | — | — | — | — | — | (0.2) | (1.1) | (1.9) |
| EBIT | (5.7) | (7.2) | (4.7) | (6.8) | (15.1) | (11.7) | (8.5) | (3.5) | (2.8) | (4.0) | (11.0) | — | — | (0.2) | (1.1) | (1.9) |
| Effective Tax Rate | — | — | — | -3.2% | -5.1% | -7.4% | 2.0% | 1.9% | 5.7% | -0.0% | -0.0% | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.